LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

Search

Myriad Genetics Inc

Open

SectorHealthcare

5.26 0.57

Overview

Share price change

24h

Current

Min

5.15

Max

5.46

Key metrics

By Trading Economics

Income

42M

-100K

Sales

-15M

196M

EPS

-0.03

Profit margin

-0.051

Employees

2,700

EBITDA

-12M

-14M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+68.75% upside

Dividends

By Dow Jones

Next Earnings

5 sie 2025

Market Stats

By TradingEconomics

Market Cap

-869M

448M

Previous open

4.69

Previous close

5.26

News Sentiment

By Acuity

38%

62%

125 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Myriad Genetics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 cze 2025, 23:49 UTC

Earnings

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 cze 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 cze 2025, 21:30 UTC

Earnings

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 cze 2025, 21:07 UTC

Earnings

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 cze 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 cze 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 cze 2025, 23:34 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 cze 2025, 23:33 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 cze 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 cze 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 cze 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 cze 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 cze 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 cze 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 cze 2025, 23:19 UTC

Acquisitions, Mergers, Takeovers

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 cze 2025, 22:06 UTC

Earnings

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 cze 2025, 21:15 UTC

Earnings

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 cze 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 cze 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 cze 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 cze 2025, 21:07 UTC

Earnings

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 cze 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 cze 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 cze 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 cze 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 cze 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 cze 2025, 20:52 UTC

Earnings

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 cze 2025, 20:51 UTC

Earnings

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 cze 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 cze 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Myriad Genetics Inc Forecast

Price Target

By TipRanks

68.75% upside

12 Months Forecast

Average 8.64 USD  68.75%

High 18 USD

Low 4 USD

Based on 14 Wall Street analysts offering 12 month price targets forMyriad Genetics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

14 ratings

4

Buy

8

Hold

2

Sell

Technical Score

By Trading Central

N/A / 7.55Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

125 / 380 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.